ADVM is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,
ADVM is set to present additional clinical data for the first cohort of patients (n=6) in the OPTIC phase 1 clinical trial of ADVM-022, intra-vitreal injection gene therapy in wet age-related macular degeneration (wet AMD ) at the Retina Sub-specialty Day Program of the American Academy of Ophthalmology (AAO) 2019 Annual Meeting in San Francisco, CA.
NEXT EARNING: Nov 11, 2019
MARKET CAP: $333.254 Million
-Fibonacci 876 retracement is an important reversal level in high trades.
-Our MS Signal oscillator indicating moving higher and now being a potential good time to buy for a bounce.
-MS Squeeze also indicating that bulls are re-gaining control (over mid-line suggests potential squeeze incoming)
Please like, share, and follow so I can continue finding awesome trades. Check out MS Money Trade Ideas for pre-researched trades to add to your watchlist!! Thanks in advance.
Disclosure: I am long ADVM . I may buy or sell within the next 72 hours. This is not a recommendation to buy or sell. Please do your homework before investing.